[Hypertension and stroke: new publications in 2005].
Current studies confirm the previous European recommendations according to which the individual evaluation of the patient's risk is superior to a breakdown into general therapeutic groups. Studies on primary prevention show that patients with atrial fibrillation in particular obtain greater benefit from losartan than from atenolol, and that even a small reduction in blood pressure reduced the stroke risk. The greatest benefit was seen in those patients in whom the target pressure was achieved within a period of six months. The combination of a calcium antagonist and an ACE inhibitor prevented significantly more strokes than the combination of a beta blocker and a diuretic. In studies investigators secondary prevention a sartan was found to prevent more cardiovascular events than nitrendipine.